* CYTOMICS *
2000 - IDF
Orsay
(near Paris)
www.cytomics.fr Discovery, Drugs
Key words: Ubiquitin ligases, UbiScreen, High-throughput Screening, Cancer, Nosocomial Fungal Infections
Mission: to discover and develop small molecules controlling protein turnover, to treat serious human diseases, notably inflammatory diseases and cancer and nosocomial fungal infections
Clients: Prescribers
info@cytomics.fr
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS | | Start-up |
Managing Dir.: Cambou (Bernard) [born 1955, MBA (Essec), ex-StageMark (co-founder), Aventis-Principia, HGS, MIT]
Sc.Dir.: Hercend (Thierry) [born 1952, oncologist]
Fin.Dir.: Martin (Erwan) [Sup de Co (Toulouse), MBA, ex-Syndex]
BusDev:
Financers: Société Générale A.M., Edmond de Rotschild I.P., Truffle Venture | Turnover (M€) : none (2006)
Total funding (M€) : 13.0
Last funding (M€) : 10.0
Focus : Cancers
Position : Preclin
Company confirm : neutral |
History | DATE | MILESTONE | TYPE | TIME | | 2007 .10 | Financing (no interest loan) : 2.1 M€, by OSEO, to support its ongoing program in the anti-fungal area (second Oseo grant) | DEBT | [7 years] |
| 2007 .03 | Nomination : Bernard Cambou, new CEO, Prof. Dominique Thomas, founder, resigns | ORGN | [7 years] |
| 2006 .02 | 2nd round-financing : 10.0 M€, by Edmond de Rotschild I.P., Truffle Venture and previous shareholders | RFINB | [6 years] |
| 2003 .02 | 1st round-financing : 3.0 M€, by Société Générale A.M., and others | RFINA | [3 years] |
| 2000 .04 | Company founded by Dominique Thomas, at initially, Gif-sur-Yvette (near Paris), in collaboration with Richard Benarous (initially as Cytomics Systems, then from February 2008, as Cytomics Pharmaceuticals) | ORGF | [0 year] | Actualisation / Updating: 31-Oct-2008 |
|
